Skip to main
ANNX

Annexon, Inc (ANNX) Stock Forecast & Price Target

Annexon, Inc (ANNX) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Annexon Inc., a clinical-stage biopharmaceutical company, is developing innovative therapies targeting complement-mediated disorders through its platform technology, which focuses on the crucial role of C1q activation. Positive results from the ANX005 clinical trials, demonstrating a significant improvement in recovery metrics compared to standard therapies and a favorable risk profile, highlight the therapeutic potential and market differentiation of its product pipeline. Additionally, the early completion of Phase 3 enrollment for ANX007, coupled with its recognition in the EMA's PRIME PDC pilot program, underlines the company's commitment to advancing its vision preservation goals, suggesting a robust regulatory pathway for future product approvals.

Bears say

Annexon Inc has faced significant financial challenges, highlighted by a substantial net loss of $49.2 million, or $0.34 per share, indicating pressure on profitability as the company progresses through its clinical trials. The key risks, particularly surrounding the potential failure of its lead product candidate ANX005 in clinical studies and its ability to secure regulatory approvals in both the US and EU, raise concerns over the future viability of its revenue projections and market penetration. Furthermore, uncertainties regarding the ability of ANX005 to achieve peak commercial revenue estimates based on market size and pricing further diminish the outlook for the company's financial performance.

Annexon, Inc (ANNX) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Annexon, Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Annexon, Inc (ANNX) Forecast

Analysts have given Annexon, Inc (ANNX) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Annexon, Inc (ANNX) has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Annexon, Inc (ANNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.